Drugs in MeSH Category Miotics

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epic Pharma Llc	OCUSERT PILO-20	pilocarpine	INSERT, EXTENDED RELEASE;OPHTHALMIC	017431-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Fera Pharms Llc	PHOSPHOLINE IODIDE	echothiophate iodide	FOR SOLUTION;OPHTHALMIC	011963-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes
Fera Pharms Llc	PHOSPHOLINE IODIDE	echothiophate iodide	FOR SOLUTION;OPHTHALMIC	011963-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Methapharm	PROVOCHOLINE	methacholine chloride	FOR SOLUTION;INHALATION	019193-001	Oct 31, 1986		RX	Yes	Yes
Methapharm	PROVOCHOLINE	methacholine chloride	FOR SOLUTION;INHALATION	019193-002	Aug 29, 2016		DISCN	Yes	No
Pharmafair	CARBACHOL	carbachol	SOLUTION;INTRAOCULAR	070292-001	May 21, 1986		DISCN	No	No

Miotics Market Analysis and Financial Projection

The ophthalmic drugs market, particularly drugs classified under the MeSH term "Miotics" (agents causing pupil contraction), is shaped by evolving therapeutic applications, demographic trends, and strategic patent management. Below is a structured analysis of market dynamics and the patent landscape:

---

Market Dynamics

Growth Drivers

• The global ophthalmic drugs market is projected to grow from $38.6 billion in 2023 to $85.6 billion by 2033, at a CAGR of 8.3%[5]. Miotics, including parasympathomimetics like pilocarpine, contribute to this growth due to their use in glaucoma and newer applications like presbyopia treatment[13].
• Aging populations and rising prevalence of eye disorders (e.g., glaucoma, diabetic retinopathy) are key demand drivers. Anti-glaucoma drugs, a category that includes miotics, dominate the market with a 31.9% share[5].
• Recent innovations, such as 1.25% pilocarpine (Vuity) for presbyopia, have revitalized interest in miotics, expanding their use beyond traditional IOP-lowering applications[13][14].

Market Segmentation

• By Indication: Miotics are primarily used for glaucoma, infections/inflammation, and retinal disorders. Emerging applications include reversal of mydriasis (e.g., Nyxol/phentolamine)[14] and presbyopia[13].
• By Drug Class: Anti-glaucoma drugs hold the largest market share (31.9%)[5].
• By Formulation: Eye drops dominate (41.8% share) due to ease of use and OTC availability[5].

Competitive Landscape

• Major players include AbbVie (Vuity), Novartis, Alcon, and Ocuphire Pharma[5][14].
• North America leads regional markets (44% share), driven by advanced healthcare infrastructure and high R&D investment[5].

---

Patent Landscape

Key Trends and Strategies

• Evergreening: Pharmaceutical companies file ~125 patent applications per drug on average to extend exclusivity beyond 20 years. For example, AbbVie’s 247 patent applications for Humira illustrate aggressive lifecycle management[10].
• Formulation and Delivery Innovations: New patents focus on improved delivery mechanisms. Ocuphire’s Nyxol (phentolamine mesylate) secured a U.S. patent until 2039 for reversing mydriasis by selectively targeting iris muscles without affecting the ciliary muscle[14].
• Geographic Expansion: Patent filings are concentrated in the U.S., China, Japan, and Europe, reflecting market priorities[11].

Legal and Regulatory Challenges

• Patent Cliffs: Over 50% of Intuitive Surgical’s patents (robotic surgery) expire by 2027[2], highlighting broader risks for medical innovators. However, miotics like pilocarpine face generic competition earlier due to older core patents.
• Litigation Risks: The FTC has scrutinized "product hopping" strategies (e.g., Novartis’s Miochol-E), where minor formulation changes delay generics[12].

---

Technological and Clinical Shifts

• Presbyopia Focus: Vuity’s FDA approval (2021) signals a shift toward age-related eye disorders, leveraging low-dose pilocarpine to improve near vision[13].
• Combination Therapies: Patents increasingly cover synergistic drug-device combinations (e.g., miotics with intraocular lenses)[11].

---

Key Takeaways

1. Market Growth: Miotics remain critical in glaucoma management, with expanding roles in presbyopia and mydriasis reversal.
2. Innovation-Driven Patents: New formulations and delivery methods drive patent activity, exemplified by Nyxol’s extended protection[14].
3. Legal Risks: Evergreening tactics face regulatory pushback, necessitating balanced IP strategies[10][12].

---

"The strategic use of patents to extend monopolies has significant consequences on healthcare costs, but innovation in drug delivery continues to unlock new therapeutic potentials." – Analysis of ophthalmic market trends[5][10].

This landscape underscores the interplay of clinical need, innovation, and IP strategy in shaping the miotics market.

References

1. https://www.knowledge-sourcing.com/report/global-ophthalmic-drugs-market
2. https://www.mddionline.com/business/an-overview-of-the-robotic-surgery-patent-landscape
3. https://decs.bvsalud.org/en/ths/?filter=ths_termall&q=Miotics
4. https://ec.europa.eu/docsroom/documents/7650/attachments/1/translations/en/renditions/pdf
5. https://market.us/report/ophthalmic-drugs-market/
6. https://www.uspto.gov/sites/default/files/documents/2014ig_f_schindler_2015mar16.pdf
7. https://en.wikipedia.org/wiki/Medical_Subject_Headings
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC3654871/
9. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4648623
10. https://www.i-mak.org/wp-content/uploads/2018/08/I-MAK-Overpatented-Overpriced-Report.pdf
11. https://www.maxval.com/wp-content/uploads/2021/12/Ophthalmic-Devices-MaxVal.pdf
12. https://www.ftc.gov/sites/default/files/documents/cases/2010/10/101001novartisdo_0.pdf
13. https://www.presbyopiaphysician.com/issues/2022/june/an-evidence-based-guide-to-retinal-complications-and-miotics/
14. https://ir.opusgtx.com/press-releases/detail/378/ocuphire-extends-u-s-patent-protection-for-late-stage-drug-candidate-nyxol-for-reversal-of-mydriasis-by-five-more-years-into-2039-with-new-patent-issuance
15. https://www.citiusminds.com/service-offerings/patent-landscape-analysis/